[go: up one dir, main page]

MX2018010291A - Vacunas novedosas contra el virus de zika. - Google Patents

Vacunas novedosas contra el virus de zika.

Info

Publication number
MX2018010291A
MX2018010291A MX2018010291A MX2018010291A MX2018010291A MX 2018010291 A MX2018010291 A MX 2018010291A MX 2018010291 A MX2018010291 A MX 2018010291A MX 2018010291 A MX2018010291 A MX 2018010291A MX 2018010291 A MX2018010291 A MX 2018010291A
Authority
MX
Mexico
Prior art keywords
mammal
zika
zika virus
immune response
plasmid dna
Prior art date
Application number
MX2018010291A
Other languages
English (en)
Inventor
Muthumani Karuppiah
Weiner David
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2018010291A publication Critical patent/MX2018010291A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un aspecto de la presente invención se refiere a construcciones de ácido nucleico capaces de expresar un antígeno de Zika que provoca una respuesta inmunitaria en un mamífero contra el virus de Zika, y métodos de usos de estas. Además, hay vacunas de plásmidos de ADN capaces de generar una respuesta inmunitaria contra un virus de Zika en un mamífero, que comprenden un plásmido de ADN y un excipiente farmacéuticamente aceptable y métodos de uso de estas. El plásmido de ADN es capaz de expresar un antígeno de Zika en una célula del mamífero en una cantidad efectiva para provocar una respuesta inmunitaria en el mamífero que tenga reactividad cruzada frente a todas las cepas de Zika.
MX2018010291A 2016-02-25 2017-02-24 Vacunas novedosas contra el virus de zika. MX2018010291A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662300030P 2016-02-25 2016-02-25
US201662305183P 2016-03-08 2016-03-08
US201662396742P 2016-09-19 2016-09-19
US201662417100P 2016-11-03 2016-11-03
US201762462249P 2017-02-22 2017-02-22
PCT/US2017/019407 WO2017147458A1 (en) 2016-02-25 2017-02-24 Novel vaccines against zika virus

Publications (1)

Publication Number Publication Date
MX2018010291A true MX2018010291A (es) 2019-06-06

Family

ID=59685658

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018010291A MX2018010291A (es) 2016-02-25 2017-02-24 Vacunas novedosas contra el virus de zika.
MX2023006203A MX2023006203A (es) 2016-02-25 2018-08-24 Vacunas novedosas contra el virus de zika.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023006203A MX2023006203A (es) 2016-02-25 2018-08-24 Vacunas novedosas contra el virus de zika.

Country Status (10)

Country Link
US (2) US11648303B2 (es)
EP (1) EP3419660A4 (es)
JP (3) JP7012365B2 (es)
KR (1) KR20190003471A (es)
CN (2) CN109152826B (es)
AU (3) AU2017222644B2 (es)
BR (1) BR112018017307A2 (es)
CA (1) CA3015792A1 (es)
MX (2) MX2018010291A (es)
WO (1) WO2017147458A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
EP4218805A1 (en) 2015-07-21 2023-08-02 ModernaTX, Inc. Infectious disease vaccines
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
CA3015792A1 (en) * 2016-02-25 2017-08-31 The Trustees Of The University Of Pennsylvania Novel vaccines against zika virus
US11666649B2 (en) * 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
US11806393B2 (en) * 2017-02-10 2023-11-07 La Jolla Institute For Allergy And Immunology Flavivirus peptide sequences, epitopes, and methods and uses thereof
EP3582790A4 (en) 2017-02-16 2020-11-25 ModernaTX, Inc. VERY POWERFUL IMMUNOGENIC COMPOSITIONS
WO2019055807A1 (en) 2017-09-14 2019-03-21 Modernatx, Inc. RNA VACCINES AGAINST ZIKA VIRUS
CN111615397B (zh) 2017-11-03 2024-09-13 武田疫苗股份有限公司 寨卡疫苗和免疫原性组合物及其使用方法
MX2020005554A (es) 2017-11-30 2020-10-12 Takeda Vaccines Inc Vacunas y composiciones inmunogenas para zika y metodos para usarlas.
US11491217B2 (en) 2017-12-06 2022-11-08 Emory University Chimeric viruses encoding mutant zika virus envelope glycoproteins
BR112021001195A2 (pt) * 2018-07-23 2021-04-27 The University Of Adelaide vacina, composição farmacêutica, peptídeo imunogênico isolado, composição, métodos para elicitar uma resposta imune em um sujeito, para produzir um anticorpo antiproteína ns1 de zika, para detectar uma infecção por zica vírus e para detectar células t específicas de zika vírus, e, uso de uma vacina, uma composição farmacêutica, um peptídeo imunogênico isolado ou uma composição.
BR112021008217A2 (pt) * 2018-10-31 2021-08-17 Icahn School Of Medicine At Mount Sinai anticorpos humanos que têm como alvo vírus zika ns1, polipeptídeos ns1 e seus usos
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
EP4306641A4 (en) * 2021-02-05 2025-06-04 ST Pharm Co., Ltd. NEW NUCLEIC ACID MOLECULE

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2341354C (en) * 1998-09-02 2009-10-20 The Government Of The United States Of America Dengue viruses that are replication defective in mosquitos for use as vaccines
WO2007094854A2 (en) 2005-12-14 2007-08-23 The Board Of Regents Of The University Of Oklahoma Rna virus vaccines and methods
CA2708668C (en) * 2008-01-11 2019-03-05 Vgx Pharmaceuticals, Llc Vaccines against multiple subtypes of dengue virus
JP5763541B2 (ja) 2008-11-17 2015-08-12 イノビオ ファーマシューティカルズ，インコーポレイティド フラビウイルスに対する免疫反応を引き起こす抗原及びその使用方法
KR20120093163A (ko) * 2009-09-14 2012-08-22 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ｉｌ-15 수용체 알파 및/또는 이를 인코딩하는 핵산 분자를 포함하는 백신 및 면역 치료제, 및 이를 이용하는 방법
US9109014B2 (en) 2009-11-02 2015-08-18 The Trustees Of The University Of Pennsylvania Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom
US8691961B1 (en) * 2009-11-09 2014-04-08 Integral Molecular, Inc. Flavivirus reporter virus and methods of making and using the same
WO2011115583A1 (en) * 2010-03-19 2011-09-22 National University Of Singapore A novel platform for retrovirus-like particle (vlp)-display of vaccine antigens
US10081795B2 (en) * 2010-03-24 2018-09-25 Research Development Foundation Flavivirus host range mutations and uses thereof
BR112013014457A8 (pt) * 2010-12-09 2017-12-19 Pasteur Institut usos da enzima 6-metilguanina-dna-metiltrasferase (mgmt, ec 2.1.1.63) para aumentar a produção de proteína heteróloga, bem como vetor de expressão, células recombinantes e polipeptídeo de fusão compreendendo sinal de secreção peptídica e proteína snap
KR20140007404A (ko) 2011-01-31 2014-01-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 신규 허피스 항원을 암호화하는 핵산 분자, 이것을 포함하는 백신 및 이것의 사용 방법
BR112014013745B1 (pt) * 2011-12-09 2022-06-14 Institut Pasteur Método de teste in vitro, kit de detecção e seu uso, método in vitro de diagnóstico, método de fabricação de kit, e teste de imunosseleção multiplex
CA2906082A1 (en) * 2013-03-15 2014-09-18 Inovio Pharmaceuticals, Inc. Novel vaccines against multiple subtypes of dengue virus
AU2016291836A1 (en) * 2015-07-16 2018-03-08 Bharat Biotech International Limited Vaccine compositions
EP4218805A1 (en) 2015-07-21 2023-08-02 ModernaTX, Inc. Infectious disease vaccines
WO2017070624A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
US11723967B2 (en) * 2016-02-17 2023-08-15 CureVac SE Zika virus vaccine
CA3015792A1 (en) * 2016-02-25 2017-08-31 The Trustees Of The University Of Pennsylvania Novel vaccines against zika virus
US9833505B1 (en) * 2016-07-18 2017-12-05 Variation Biotechnologies Inc. Vaccine compositions for treatment of Zika virus
KR20240090525A (ko) * 2016-09-19 2024-06-21 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 지카바이러스에 대항하는 신규한 백신 및 지카바이러스에 대해 사용하기 위한 dna 항체 작제물의 조합
AU2018207408B2 (en) * 2017-01-11 2025-02-27 The Trustees Of The University Of Pennsylvania Nucleoside-modified RNA for inducing an immune response against Zika virus
EP3412307A1 (en) * 2017-06-07 2018-12-12 Institut Pasteur Recombinant measles virus expressing zika virus proteins and their applications

Also Published As

Publication number Publication date
AU2017222644B2 (en) 2021-07-29
KR20190003471A (ko) 2019-01-09
EP3419660A1 (en) 2019-01-02
MX2023006203A (es) 2023-06-12
JP2022023241A (ja) 2022-02-07
AU2021258056A1 (en) 2021-11-25
CA3015792A1 (en) 2017-08-31
AU2017222644A1 (en) 2018-09-13
JP7555325B2 (ja) 2024-09-24
US11648303B2 (en) 2023-05-16
EP3419660A4 (en) 2019-11-06
BR112018017307A2 (pt) 2019-01-08
WO2017147458A1 (en) 2017-08-31
JP2019506175A (ja) 2019-03-07
AU2024204641A1 (en) 2024-07-25
JP7012365B2 (ja) 2022-03-04
AU2021258056B2 (en) 2024-04-04
CN115927399A (zh) 2023-04-07
US20210315987A1 (en) 2021-10-14
CN109152826B (zh) 2022-11-04
JP2024096281A (ja) 2024-07-12
US12419945B2 (en) 2025-09-23
CN109152826A (zh) 2019-01-04
US20240115689A1 (en) 2024-04-11

Similar Documents

Publication Publication Date Title
MX2018010291A (es) Vacunas novedosas contra el virus de zika.
MX2010007461A (es) Nuevas vacunas contra multiples subtipos del virus del dengue.
Liu Immunologic basis of vaccine vectors
CO2021004188A2 (es) Vacuna contra el virus de la peste porcina africana
CO2018005258A2 (es) Vacuna del virus herpes simple
CL2017000987A1 (es) Partículas tipo virus modificadas de cmv
ZA202206809B (en) Hiv vaccines comprising one or more population episensus antigens
MX2023012264A (es) Mejora del efecto de celulas t dise?adas por car por medio de vacunacion con acido nucleico.
AR110632A1 (es) Vectores del adenovirus canino
UY33297A (es) Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas
WO2010044919A3 (en) Smallpox dna vaccine and the antigens therein that elicit an immune response
CO2017007105A2 (es) Nuevos virus de tilapia
EA201992282A1 (ru) Усовершенствованные вакцины против вируса папилломы человека и способы их применения
EA201891124A3 (ru) Новые мукозные адъюванты и системы доставки
MX2017005687A (es) Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
RU2016116988A (ru) Вакцина против haemophilus parasuis серологического типа 4
MX2022007398A (es) Vacunas contra el virus de la fiebre porcina africana y métodos para usarlas.
AR089995A1 (es) Vacunas de subunidades de rotavirus, metodos de preparacion y uso de las mismas
ECSP12012131A (es) Método, plasmideo y composición para inducir una respuesta inmune contra virus de la dengue basado en vacunas de adn y virus quiméricos
CL2012003219A1 (es) Parapoxvirus recombinante que comprende un parapoxvirus y adn heterólogo derivado de un virus de la rabia; procedimiento de preparación de dicho parapoxvirus; composicion inmunogénica; uso de la composicion para inducir respuesta inmunitaria contra el virus de la rabia en un animal.
AR066823A1 (es) Aumento del rendimiento en plantas por modulacion del factor zmrr10-p de transcripcion de garp
WO2015048796A3 (en) Mosaic hiv envelope immunogenic polypeptides
BR112014014390A2 (pt) levedura recombinante, seus usos, processo para vacinação, oligonucleotídeo, vetor de expressão, e método de produção de uma composição de vacina
MX2015011485A (es) Nuevas vacunas contra multiples subtipos del virus del dengue.
ECSP14023407A (es) Virus de la enfermedad de marek modificado y vacunas elaboradas con él